MelliCell, Inc.
Aaron Glieberman currently serves as the Director of Platform Development at MelliCell, Inc., focusing on adapting cell assays for high throughput drug screening and overseeing the development of an automated data processing pipeline in Python. Prior to this role, Aaron was a Senior Engineer in Platform Development at Harvard University and worked on continuous hormone sensors, as well as organ-on-chip technology during graduate studies. Aaron’s extensive experience includes positions at Fraunhofer USA and MIT, where research efforts spanned lab-on-a-chip devices and synthetic biology, complemented by a background in emergency medical response and health and safety instruction. Aaron holds a PhD in Engineering Sciences from Harvard University, along with degrees in Biomedical Engineering from Brown University.
This person is not in any teams
MelliCell, Inc.
MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model of weight gain in human fat cells in vitro. Our core technology enables discovery of therapeutic targets and leads, while reducing the time and money required for efficacy screening. It efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes of mature fat cells in adults. Changes in fat cell size are how adults gain (or lose) weight, and increased fat cell size predicts diabetes better than obesity per se. The products we develop will treat obesity and diabetes by shrinking fat cell size and by preventing compromised metabolism in enlarged cells. We differentiate ourselves from existing therapies (e.g. GLP-1 analogs, SGLT2 inhibitors, anorexiants, intestinal lipase inhibitors, insulin secretagogues) by focusing on adipocyte-intrinsic mechanisms of action enabled by our core technology.